Published on 19/03/2015 by admin
Filed under Dermatology
Last modified 19/03/2015
This article have been viewed 1415 times
Tanya N. Basu, Chrystalla Macedo and Richard C.D. Staughton
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports
First described in 1983, bacillary angiomatosis (BA) is a vasculoproliferative disorder caused by the bacteria Bartonella henselae and Bartonella quintana (previously Rochalimaea spp.). It typically presents in profoundly immunocompromised patients (e.g., in advanced HIV infection, post transplant or during cytotoxic chemotherapy). Angiomatous papules, nodules, or plaques may arise in the skin or systemically in any organ including the bone, central nervous system, liver, where the condition is termed peliosis hepatis, and spleen (peliosis splenis).
Vascular proliferation may be due to an angiogenic factor produced by the Bartonella genus. B. henselae is transmitted through a cat scratch or bite; it also causes cat scratch disease. B. quintana is transmitted by the human body louse and also causes trench fever. Virtually identical localized cutaneous lesions to BA are seen in verruga peruana, which occurs in Peru due to the related Bartonella bacilliformis, transmitted by sandflies.
Prompt diagnosis of bacillary angiomatosis is essential to prevent dissemination, which can be fatal. Clinical suspicion should be aroused in the context of a low CD4 lymphocyte count (<100) or other immunosuppression, especially with a history of exposure to cats (harboring B. henselae) or body lice (which carry B. quintana). Cutaneous lesions can be superficial cherry-red round papules with an eroded surface, similar to pyogenic granulomas, or violaceous, lichenoid plaques or deep subcutaneous nodules. Single lesions have been reported in immunocompetent patients at inoculation sites whereas in the immunocompromised the entire body surface may be affected. Lesions can be mistaken for Kaposi sarcoma or in-transit metastatic amelanotic melanoma and other malignancies because of the highly vascular and erosive nature of the lesions. In advanced HIV infections, differentials include deep fungal infection, e.g., cryptococcosis and histoplasmosis. Patients with extracutaneous disease may or may not have skin signs and can present with vomiting, abdominal pain, and deranged liver function (peliosis hepatis) or pancytopenia and splenomegaly (peliosis splenis). Presentation can also include fever, lymphadenopathy, night sweats, endocarditis, and anemia.
Histology allows easy differentiation and shows a lobular proliferation of capillaries and venules, with swollen endothelial cells containing clumps of bacteria.
The response of bacillary angiomatosis to antibiotic treatment is usually dramatic, in contrast to the response of cat scratch disease. Our drugs of first choice are the macrolides (e.g., erythromycin 500 mg four times daily, azithromycin 500 mg daily, clarithromycin 500 mg twice daily); doxycycline 100 mg twice daily as an alternative; intravenous treatment may be needed in severe disease or with gastrointestinal intolerance. Their use is based on anecdotal experience in the absence of systematic trials. Current recommendations are that treatment should be continued for 3 months where there is skin disease only, and 4 months where there is bone/visceral involvement or peliosis hepatis. Should relapse occur on the above regimens, long-term prophylaxis with erythromycin or doxycycline may be indicated. In practice, however, the introduction of highly active anti-retroviral therapy (HAART) should reverse the immunocompromise state and thus alter the response to treatment, making long-term antibiotic less necessary (although BA has been reported during immune reconstitution during HAART). The patient should be evaluated for parenchymal and osseous disease prior to treatment and warned that a Jarisch–Herxheimer reaction may occur after the first few doses of antibiotic.
A wide variety of therapeutic agents are mentioned in the literature, but there is a lack of correlation between the in vitro and in vivo drug susceptibility of Bartonella spp., which reduces the usefulness of laboratory data. The picture is clouded further by the different response of Bartonella spp. to drugs in each of the diseases it causes.
Full blood count, liver function tests, and CD4 lymphocyte count
Biopsy and Warthin–Starry stains/electron microscopy
Prolonged culture of blood and biopsy tissue
Polymerase chain reaction of biopsy material
Serology – indirect fluorescence assay
Culture of the fastidious Gram negative rods of Bartonella
Treatment of Skin Disease Comprehensive Therapeutic Strategies 4e
WhatsApp us
